Back to today’s briefing

Story perspectives

FDA Approves Zepbound: New Hope for Sleep Apnea

1/17/2025

50 8

Summary

Story summary

The FDA has made a groundbreaking decision by approving Zepbound, the first-ever medication for patients with obstructive sleep apnea linked to obesity. Dr. Stella Hahn from Northwell Health emphasizes its importance in broadening treatment choices beyond traditional CPAP machines. Promising study results indicate Zepbound not only alleviates sleep apnea but also offers hope for future weight-loss therapies.

1 of 1

Story summary

The FDA has made a groundbreaking decision by approving Zepbound, the first-ever medication for patients with obstructive sleep apnea linked to obesity. Dr. Stella Hahn from Northwell Health emphasizes its importance in broadening treatment choices beyond traditional CPAP machines. Promising study results indicate Zepbound not only alleviates sleep apnea but also offers hope for future weight-loss therapies.